BioGenCell’s mission is to develop an innovative technology platform that will enable the rapid creation of easy-to-use and cost-effective treatments for a wide range of degenerative diseases using highly standardized therapies derived from adult stem cells.
Prof. Michael Belkin, MD
Prof. Belkin has been involved in biotechnology ventures since the creation of the field and was involved in the establishment of over 15 medical start-ups in ophthalmology and other fields. He also serves as a consultant to numerous biotechnology projects and companies.
Prof. Belkin is currently a professor of Ophthalmology and the incumbent of the Fox Chair of Ophthalmology in Tel-Aviv University. He is also the director of the Ophthalmic Technologies Laboratory at the university’s Eye Research Institute located at the Sheba Medical Center, Israel, and serves as senior advisor to the Singapore Eye Research Institute.
Prof. Belkin served previously as Director of Research, Development and Non-conventional Warfare Medicine in the Israel Defense Forces’ Medical Corps, was the first full-time director of the Tel Aviv University Eye Research Institute, Chairman of the Tel-Aviv University Department of Ophthalmology and President of the Israel Society of Eye and Vision Research of which he was a founder.
Prof. Belkin, who is the author of over 200 scientific publications and holds 15 patents, received an MA in Science from Cambridge University, England, and a PhD in Medicine from the Hebrew University of Jerusalem, Israel.